// App-Quantinova.ai

2417 : Elevated interleukin-6 and interleukin-18 concentrations predict residual inflammatory risk both before and after interleukin-1beta inhibition with canakinumab

Researchers

Presenter

  • PM Ridker

Principal Investigators

  • J Macfadyen

  • T Thuren

  • P Libby

Medical Centers

  • Brigham and Women's Hospital, MA

Locations

  • N/A

Companies

  • N/A

Study Components

Therapeutic Area

  • Cardiovascular (CVS)

  • Blood/haematological Diseases

  • Pulmonary/Respiratory Diseases

Disease

  • Post-myocardial infarction

  • Atherothrombosis

  • Venous thrombosis

Biomarkers

  • Interleukin 18

  • Interleukin 6

  • NLR family pyrin domain containing 3

Drug/Treatment

  • ILS-969

  • canakinumab (SC)

  • Interleukin

Outcome

  • N/A

Study Design

  • Randomized

  • Placebo Control

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved